Company Overview: Celator Pharmaceuticals

Industry News

7 Jul

Celator® Pharmaceuticals to Host Analyst and Investor Day on July 16, 2015

Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the company will host an Analyst and Investor Day on Thursday, July 16, 2015, from 9:00am to 12:00pm ET at the Omni...

Read more

29 Jun

The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML

– This is part of the existing $5 Million Therapy Acceleration Program partnership – – Accelerated payment based on recently reported positive induction response rate – Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that The Leukemia & Lymphoma Society® (LLS) is accelerating a portion of the final payment linked to the...

Read more

24 Jun

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

CPX-351 demonstrates a 43.2% relative improvement in induction response rate Conference call today at 8:30am Eastern Time to discuss the results Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study...

Read more

3 Jun

Celator® Pharmaceuticals Announces Enrollment is Complete in CPX-351 Phase 2 Study

– Encouraging response rate achieved; including patients with high-risk (secondary) AML (the Phase 3 study population), de novo AML, relapsed AML, and relapsed ALL – Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer,...

Read more

1 Apr

Celator® Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference

Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the 14th Annual Needham Healthcare Conference on Tuesday, April...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address